AdAlta Ltd (ASX:1AD)’s Tim Oldham joins Andrew Scott from Proactive to chat about the progress of its pre-clinical program for AD-214 in the last quarter. Oldham discusses the partnering interest across AD-214's indications as well as AdAlta’s immuno-oncology programs.
AdAlta's AD-214 pre-clinical program progressing well
